Molbio Diagnostics IPO Financials
The Molbio Diagnostics IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 31 Mar 2026, Molbio Diagnostics Limited reported assets of ₹2,148.42 crore, revenue of ₹1,455.17 crore, and a profit after tax (PAT) of ₹164.14 crore. The company had a net worth of ₹1,144.68 crore and reserves & surplus of ₹1,148.84 crore, and total borrowings are 412.64 crore.
Revenue increased by 22.28% in 31 Mar 2025 and increased by 41.56% in 31 Mar 2026, while Profit After Tax (PAT) grew by 65.88% in 31 Mar 2025 and grew by 18.44% in 31 Mar 2026, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Molbio Diagnostics Limited Financials (₹ in Crores)
| Particular | 31 Mar 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 2148.42 | 1461.56 | 1221.06 |
| Revenue | 1455.17 | 1027.94 | 840.66 |
| Profit After Tax | 164.14 | 138.58 | 83.54 |
| Net Worth | 1144.68 | 952.95 | 807.94 |
| Reserve & Surplus | 1148.84 | 990.84 | 845.48 |
| Total Borrowings | 412.64 | 123.16 | 174.58 |
EPS Pre
14.56%
EPS Post
0.00%
P/E Pre
0.00
P/E (Post Issue)
0.00x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Molbio Diagnostics Limited?
Molbio Diagnostics Limited reported revenue of ₹1455.17 crore as of 31 Mar 2026. Revenue figures from the Molbio Diagnostics IPO provide insights into sales growth, market demand, and business scalability.
What is the EBITDA of Molbio Diagnostics Limited?
Molbio Diagnostics Limited reported an EBITDA of ₹328.24 crore as of 31 Mar 2026. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures the company's operating profitability and reflects its core business performance before non-operating expenses.
What is the Profit After Tax (PAT) of Molbio Diagnostics Limited?
Molbio Diagnostics Limited reported a Profit After Tax (PAT) of ₹164.14 crore as of 31 Mar 2026. PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Molbio Diagnostics Limited?
Molbio Diagnostics Limited has a Price-to-Earnings (P/E) ratio of 0x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.